科研之友
微信
新浪微博
Facebook
分享链接
摘要
Natalizumab is a monoclonal antibody against alpha 4 beta 1 integrines and is licensed since 2006 for the treatment of highly active MS patients. Beyond progressive multifocal leucen-cephalopathy (PMS) allergic reactions are the most serious adverse events of natalizumab that occur predominantly early in the disease course. Here we describe different types of hypersensitivity syndromes during therapy with natalizumab.
- 出版日期2010
